SCHEMBL4603708

SCHEMBL4603708

Cc1cc(F)ccc1N1CCC(=O)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.48
KMT2A Q03164 2/20 0.48
GAA P10253 3/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ADAMTS5 Q9UNA0 1/20 0.44
DRD2 P14416 1/20 0.44
DRD4 P21917 1/20 0.44
HTR7 P34969 1/20 0.43
ALDH1A3 P47895 2/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
P2RX7 Q99572 1/20 0.42
PARP1 P09874 2/20 0.42
MAPT P10636 3/20 0.41
MEN1 O00255 1/20 0.41
THRB P10828 1/20 0.41
NR4A1 P22736 1/20 0.41
PTK2B Q14289 1/20 0.41
NOTUM Q6P988 1/20 0.41
HCAR1 Q9BXC0 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14485349 0.82 ALDH1A1 (0.62) ALDH1A1KMT2AGAASMN1; SMN2L3MBTL1
SCHEMBL21590283 0.79 MAPT (0.48) ALDH1A1KMT2AGAALMNASMN1; SMN2
SCHEMBL14922277 0.79 ALDH1A1 (0.67) ALDH1A1KMT2AGAALMNASMN1; SMN2
SCHEMBL12291137 0.77 ALDH1A1 (0.50) ALDH1A1GAALMNASMN1; SMN2DRD2
SCHEMBL30609639 0.77 HTR3A (0.61) HTR7
SCHEMBL4142914 0.77 DRD2 (0.45) ALDH1A1KMT2AGAALMNASMN1; SMN2
SCHEMBL706971 0.77 HTR3A (0.61) HTR7
SCHEMBL7711112 0.77 ALDH1A1 (0.46) ALDH1A1KMT2AGAALMNASMN1; SMN2
Hydrochloric Acid SCHEMBL709707 0.76 HTR3A (0.59) LMNAHTR7MAPT
SCHEMBL13419298 0.76 ALDH1A1 (0.59) ALDH1A1KMT2AGAALMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188290-B2 Reacting secondary amine, carbon dioxide, triarylsilyl chloride and halogenation agent GLAXO GROUP LIMITED (GB) 2012-05-29 US claimed
US-20080262234-A1 Process for Preparing N, N-Substituted Carbamoyl Halides GLAXO GROUP LIMITED 2008-10-23 US claimed
EP-1940783-A1 PROCESS FOR PREPARING N, N-SUBSTITUTED CARBAMOYL HALIDES GLAXO GROUP LIMITED (GB) 2008-07-09 EP claimed
WO-2007048642-A1 PROCESS FOR PREPARING N, N-SUBSTITUTED CARBAMOYL HALIDES GLAXO GROUP LIMITED (GB) 2007-05-03 WO claimed
US-11603368-B2 Fused thiophene derivatives and their uses ENYO PHARMA (FR) 2023-03-14 US disclosed
EP-3749658-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO Pharma (FR) 2020-12-16 EP disclosed
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2020-11-26 US disclosed
WO-2019154949-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES ENYO PHARMA (FR) 2019-08-15 WO disclosed
US-8188290-B2 Reacting secondary amine, carbon dioxide, triarylsilyl chloride and halogenation agent GLAXO GROUP LIMITED (GB) 2012-05-29 US disclosed
CN-101959513-A Novel pharmaceutical composition GLAXO GROUP LTD 2011-01-26 CN disclosed
CN-101641099-A Pharmaceutical composition comprising 3, 5-diamino-6- (2, 3-dichlorophenyl) -1, 2, 4-triazine or R (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethylpyrimidine and NK1 GLAXO GROUP LTD GB 2010-02-03 CN disclosed
CN-101641102-A Pharmaceutical compositions comprising NK1 receptor antagonists and sodium channel blockers GLAXO GROUP LTD GB 2010-02-03 CN disclosed
CN-101568341-A Composition comprising an nk-1 receptor antagonist and an ssri for the treatment of tinnitus and hearing loss GLAXO GROUP LTD (GB) 2009-10-28 CN disclosed
US-20080262234-A1 Process for Preparing N, N-Substituted Carbamoyl Halides GLAXO GROUP LIMITED 2008-10-23 US disclosed
EP-1940783-A1 PROCESS FOR PREPARING N, N-SUBSTITUTED CARBAMOYL HALIDES GLAXO GROUP LIMITED (GB) 2008-07-09 EP disclosed
WO-2007048642-A1 PROCESS FOR PREPARING N, N-SUBSTITUTED CARBAMOYL HALIDES GLAXO GROUP LIMITED (GB) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200369682-A1 FUSED THIOPHENE DERIVATIVES AND THEIR USES FTH1, SLC40A1, FECH ALDH1A1 2143/4885KMT2A 3454/4885GAA 267/4885
US-11603368-B2 Fused thiophene derivatives and their uses FTH1, SLC40A1, FECH ALDH1A1 2143/4885KMT2A 3454/4885GAA 267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.